Orrick Continues Growth of Life Sciences & Tech Team


  • Tony Chan joins the firm as a partner focused on advising companies and investors in the life sciences and tech sectors in M&A, private equity and growth equity transactions.
  • He is the 9th lateral addition to the firm’s life sciences practice and 11th hire in Washington, D.C. in the past year.
  • Tony joins Orrick from Morgan Lewis, where he served as leader of the firm’s interdisciplinary corporate practice in Washington, D.C.

“Our tech and life sciences practices are continuing to experience extraordinary demand, as innovators and their financial backers continue making game-changing investments. As we continue to build out our holistic offerings for these sectors, we are thrilled to add Tony’s leadership to our M&A team,” said Matthew Gemello, global leader of Orrick’s Corporate practice.

“Orrick’s focus on integrated solutions by vertical is exactly what sophisticated clients demand. I am incredibly excited to collaborate with the team globally to offer something distinctive,” added Tony.

Tony is active in the community, serving on the boards of the Arlington Arts Center, the Asian Pacific American Bar Association of DC, and the Harvard Law School Association of DC.

LMG Life Sciences named Orrick its 2021 Finance & Corporate Firm to Watch. Over the past year, the firm has added Life Sciences partners in the areas of Venture, Capital Markets, Cyber & Privacy, Antitrust, White Collar, Patent Prosecution and Tech Transactions. Last month, the firm added to its Washington, D.C. office two antitrust practitioners with a Life Sciences focus: Eileen Cole from White & Case and Craig Falls from Dechert. The firm also added 20 tech-focused partners globally since 2021. 

Orrick acts for 6 of the Forbes 10 largest public tech companies, 3,700+ high growth technology businesses, and more than 500 life sciences companies.